LAKE OSWEGO, Ore., June 5, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, updated NeuVax™ (E75) results at a physician panel on Monday, June 5, 2012 during the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting in Chicago, Illinois.
